Vasopressin antagonists in heart failure.

Ladan Golestaneh, Ashok Talreja, Thierry H. Le Jemtel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalCurrent Heart Failure Reports
Volume1
Issue number4
StatePublished - Dec 2004

Fingerprint

Heart Failure
Sodium Potassium Chloride Symporter Inhibitors
Vasopressin Receptors
Hyponatremia
Arginine Vasopressin
Hypertrophy
Recurrence
Mortality
Antidiuretic Hormone Receptor Antagonists
Water
tolvaptan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Golestaneh, L., Talreja, A., & Le Jemtel, T. H. (2004). Vasopressin antagonists in heart failure. Current Heart Failure Reports, 1(4), 190-196.

Vasopressin antagonists in heart failure. / Golestaneh, Ladan; Talreja, Ashok; Le Jemtel, Thierry H.

In: Current Heart Failure Reports, Vol. 1, No. 4, 12.2004, p. 190-196.

Research output: Contribution to journalArticle

Golestaneh, L, Talreja, A & Le Jemtel, TH 2004, 'Vasopressin antagonists in heart failure.', Current Heart Failure Reports, vol. 1, no. 4, pp. 190-196.
Golestaneh, Ladan ; Talreja, Ashok ; Le Jemtel, Thierry H. / Vasopressin antagonists in heart failure. In: Current Heart Failure Reports. 2004 ; Vol. 1, No. 4. pp. 190-196.
@article{8954584a3f9b45218d62997c8282ecbe,
title = "Vasopressin antagonists in heart failure.",
abstract = "The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The {"}braking phenomenon,{"} hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as {"}vaptans{"} promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.",
author = "Ladan Golestaneh and Ashok Talreja and {Le Jemtel}, {Thierry H.}",
year = "2004",
month = "12",
language = "English (US)",
volume = "1",
pages = "190--196",
journal = "Nature Methods",
issn = "1548-7091",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Vasopressin antagonists in heart failure.

AU - Golestaneh, Ladan

AU - Talreja, Ashok

AU - Le Jemtel, Thierry H.

PY - 2004/12

Y1 - 2004/12

N2 - The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

AB - The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

UR - http://www.scopus.com/inward/record.url?scp=26044458689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044458689&partnerID=8YFLogxK

M3 - Article

C2 - 16036044

AN - SCOPUS:26044458689

VL - 1

SP - 190

EP - 196

JO - Nature Methods

JF - Nature Methods

SN - 1548-7091

IS - 4

ER -